A Phase 1b Study of OMP-305B83 Plus FOLFIRI as Second Line Therapy in Subjects With Metastatic Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Navicixizumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 04 Jan 2017 According to an OncoMed Pharmaceuticals media release, company announced the dosing of the first patient in this trial.
- 04 Jan 2017 Status changed from planning to recruiting, as per an OncoMed Pharmaceuticals media release.
- 10 Nov 2015 New trial record